Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q

被引：20
|
作者：
Starczynowski, Daniel T.
Karsan, Aly [1 ]
机构：
[1] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada
来源：
CELL CYCLE | 2010年 / 9卷 / 05期
基金：
加拿大健康研究院;
关键词：
innate immunity; myelodysplastic syndromes; RPS14; FLI1; microRNAs; NF kappa B; IDENTIFICATION; 5Q-SYNDROME;
D O I：
10.4161/cc.9.5.11156
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：855 / 856
页数：2
相关论文
共 50 条
  • [1] HEMATOLOGICAL FEATURES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A CHROMOSOME 5Q DELETION
    LEWIS, S
    OSCIER, D
    BOULTWOOD, J
    ROSS, F
    FITCHETT, M
    RACK, K
    ABRAHAMSON, G
    BUCKLE, V
    WAINSCOAT, JS
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 49 (03) : 194 - 200
  • [2] Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q
    Nimer, Stephen D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2576 - 2582
  • [3] Myelodysplastic syndromes 5q deletion in childhood
    Iriani, A.
    LEUKEMIA RESEARCH, 2013, 37 : S93 - S93
  • [4] Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
    Ganan-Gomez, I.
    Wei, Y.
    Starczynowski, D. T.
    Colla, S.
    Yang, H.
    Cabrero-Calvo, M.
    Bohannan, Z. S.
    Verma, A.
    Steidl, U.
    Garcia-Manero, G.
    LEUKEMIA, 2015, 29 (07) : 1458 - 1469
  • [5] Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
    I Gañán-Gómez
    Y Wei
    D T Starczynowski
    S Colla
    H Yang
    M Cabrero-Calvo
    Z S Bohannan
    A Verma
    U Steidl
    G Garcia-Manero
    Leukemia, 2015, 29 : 1458 - 1469
  • [6] Chromosome 5q deletion in myelodysplastic syndrome
    Dwilewicz-Trojaczek, J.
    Madry, K.
    Paluszewska, M.
    Wiater, E.
    Szmigielska, A.
    Mital, A.
    Sledziowski, P.
    Salamanczuk, Z.
    Sikorska, A.
    Helbig, G.
    Wasilewska, E.
    Biedron, M.
    Calbecka, M.
    Jedrzejczak, W. W.
    LEUKEMIA RESEARCH, 2007, 31 : S91 - S91
  • [7] Molecular pathogenesis of myelodysplastic syndromes with deletion 5q
    Lee, Jung-hoon
    List, Alan
    Sallman, David A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (03) : 203 - 209
  • [8] Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion
    Steensma, David P.
    Ebert, Benjamin L.
    BLOOD, 2013, 121 (21) : 4428 - 4428
  • [9] Atypical deletion of 5q in myelodysplastic syndromes (MDS)
    Zemanova, Z.
    Brezinova, J.
    Svobodova, K.
    Lhotska, H.
    Izakova, S.
    Lizcova, L.
    Vesela, D.
    Ransdorfova, S.
    Mendlikova, I.
    Michalova, K.
    Cermak, J.
    Jonasova, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 510 - 510
  • [10] The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
    Melchert, Magda
    Kale, Vishakha
    List, Alan
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 123 - 129
12345